Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus VICTOZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO AUTOINJECTOR versus VICTOZA.
MOUNJARO (AUTOINJECTOR) vs VICTOZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It increases glucose-dependent insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Subcutaneously once weekly; initial dose 2.5 mg for 4 weeks, then increase to 5 mg for 4 weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated; maximum 15 mg weekly.
Subcutaneous injection: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily. May further increase to 1.8 mg once daily if needed for glycemic control.
None Documented
None Documented
Terminal elimination half-life ~5 days (117 hours), supporting once-weekly dosing.
After subcutaneous administration, the terminal elimination half-life is approximately 13 hours, supporting once-daily dosing.
Renal: negligible; Fecal: primarily via biliary elimination as intact peptide; total clearance ~0.056 L/h.
Liraglutide is eliminated via degradation by general proteolysis and not by specific enzymes; the intact drug is not excreted in urine or feces. Degraded metabolites are excreted via urine and feces.
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist